Thursday, February 2 at 1 PM ET Yesterday the Duchenne community learned that Part B of the MoveDMD trial did not meet its primary endpoint, which was to demonstrate a statistically significant decrease in T2 MRI with edasalonexent after 12 weeks compared to placebo in people affected by Duchenne. There were some potential treatment-associated effects at 12 weeks in the 100 mg/kg/day treatment group when compared to placebo. Therefore, Catabasis will look to see if the signals strengthen in the…See More
"Michael the article you posted does come off in a negative light for stem cell treatments by themselves. However, DMD will need to be treated with a combination of drugs and therapies. The article talks about muscle stem cells…"